Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell Patents (Class 424/152.1)
-
Publication number: 20140147435Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.Type: ApplicationFiled: May 7, 2013Publication date: May 29, 2014Inventors: Jonathan Henry ELLIS, Paul Andrew Hamblin, Alan Peter Lewis, Paul Alexander Wilson
-
Patent number: 8734801Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: October 18, 2011Date of Patent: May 27, 2014Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8734791Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.Type: GrantFiled: February 27, 2012Date of Patent: May 27, 2014Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
-
Patent number: 8734792Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).Type: GrantFiled: May 9, 2012Date of Patent: May 27, 2014Assignee: Duke UniversityInventor: Thomas F. Tedder
-
Publication number: 20140140997Abstract: Provided are methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one agent that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.Type: ApplicationFiled: June 15, 2012Publication date: May 22, 2014Applicant: CytoDyn Inc.Inventor: Richard Trauger
-
Patent number: 8722051Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2012Date of Patent: May 13, 2014Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Publication number: 20140127131Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: October 8, 2013Publication date: May 8, 2014Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR
-
Patent number: 8715670Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.Type: GrantFiled: March 31, 2010Date of Patent: May 6, 2014Assignee: Hanwha Chemical CorporationInventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
-
Patent number: 8703149Abstract: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.Type: GrantFiled: August 23, 2011Date of Patent: April 22, 2014Assignee: The Rockefeller UniversityInventors: Charles Rice, Matthew J. Evans, Thomas Von Hahn
-
Patent number: 8697071Abstract: The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by Fc?R is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: June 15, 2012Date of Patent: April 15, 2014Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sergey Gorlatov, Christopher Rankin, Nadine Tuaillon
-
Publication number: 20140093565Abstract: The invention relates to a pharmaceutical composition comprising a HDAC inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said HDAC inhibitor or steroid may alternatively be administrated separately prior to additional treatments.Type: ApplicationFiled: March 20, 2012Publication date: April 3, 2014Applicant: VALCURIA ABInventors: Kristina Drott, Thomas Relander
-
Patent number: 8679503Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.Type: GrantFiled: July 12, 2010Date of Patent: March 25, 2014Assignee: Yale UniversityInventors: Jack A. Elias, Zhou Zhu
-
Patent number: 8679485Abstract: The present disclosure provides methodology and compositions for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX or LOXL, or a synergistic combination thereof combined with other therapeutic agents. Methods and compositions for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, are also provided. Also provided herein are methods and related compositions, medical devices, systems and kits for preventing or treating various diseases and conditions associated with fibrosis with compositions comprising inhibitors of LOX or LOXL.Type: GrantFiled: August 1, 2008Date of Patent: March 25, 2014Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
-
Publication number: 20140079710Abstract: The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.Type: ApplicationFiled: October 8, 2013Publication date: March 20, 2014Inventor: Oleg Iliich Epshtein
-
Patent number: 8673305Abstract: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.Type: GrantFiled: June 15, 2012Date of Patent: March 18, 2014Assignee: G2 Therapies LtdInventor: Charles Reay MacKay
-
Publication number: 20140065149Abstract: Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described.Type: ApplicationFiled: September 6, 2013Publication date: March 6, 2014Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Timothy C. HOEY, Lucia Beviglia
-
Patent number: 8663641Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: September 14, 2012Date of Patent: March 4, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 8663634Abstract: The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-CD3 antibodies.Type: GrantFiled: July 11, 2006Date of Patent: March 4, 2014Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Ronald Wilder, Ezio Bonvini, Leslie S. Johnson
-
Patent number: 8658167Abstract: Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g.Type: GrantFiled: December 6, 2012Date of Patent: February 25, 2014Assignee: Gilead Biologics, Inc.Inventors: Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko Tokuoka Biermann
-
Patent number: 8658168Abstract: This invention discloses monoclonal antibodies (MAbs) which have little or no signaling activity as monomers become potent anti-tumor agents when they are converted into homoconjugates. The homoconjugates exert anti-growth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and does not require an Fc portion. These conjugates are potent, anti-tumor agents.Type: GrantFiled: April 8, 2002Date of Patent: February 25, 2014Assignee: The Board of Regents of The University of Texas SystemInventors: Maria-Ana Ghetie, Jonathan W. Uhr, Ellen S. Vitetta
-
Patent number: 8652466Abstract: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an Fc?R that activates a cellular effector (“Fc?RActivating,” such as Fc?RIIA or Fc?RIIIA) and an Fc?R that inhibits a cellular effector (“Fc?RInhibiting,” such as Fc?RIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such Fc?R for the Fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.Type: GrantFiled: December 7, 2007Date of Patent: February 18, 2014Assignee: MacroGenics, Inc.Inventors: Jeffrey B. Stavenhagen, Scott Koenig
-
Patent number: 8647625Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: GrantFiled: July 26, 2005Date of Patent: February 11, 2014Assignee: Biogen Idec MA Inc.Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J. M. Hanf
-
Patent number: 8647624Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.Type: GrantFiled: January 18, 2008Date of Patent: February 11, 2014Assignee: Seattle Genetics, Inc.Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
-
Patent number: 8642036Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.Type: GrantFiled: August 2, 2004Date of Patent: February 4, 2014Assignee: Genentech, Inc.Inventor: Susan D. Hellmann
-
Patent number: 8642741Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.Type: GrantFiled: November 8, 2011Date of Patent: February 4, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Brendan J. Classon, Dimitris Skokos
-
Publication number: 20140030271Abstract: The present invention concerns monoclonal antibodies specifically binding the human HMGB1 protein and further HMGB1 proteins of mammalian origin and also concerns fragments thereof, nucleic acids encoding such antibodies or fragments thereof, as well as vectors, cells, and compositions comprising the antibodies or nucleic acids, and uses thereof.Type: ApplicationFiled: April 5, 2011Publication date: January 30, 2014Applicant: DIA.PRO DIAGNOSTIC BIOPROBES S.R.L.Inventor: Cristina Scozzesi
-
Publication number: 20140030266Abstract: The present invention relates to the discovery that altered levels of D-DT (also known as MIF-2) are associated with disorders and diseases. Thus, the present invention relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with an elevated level of D-DT. The present invention also relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with a reduced level of D-DT.Type: ApplicationFiled: November 23, 2011Publication date: January 30, 2014Applicant: Yale UniversityInventors: Richard J. Bucala, Lawrence H. Young
-
Patent number: 8637016Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.Type: GrantFiled: March 10, 2008Date of Patent: January 28, 2014Assignees: KaloBios Pharmaceuticals, Inc., Monash University, Ludwig Institute for Cancer Research LimitedInventors: Martin Lackmann, Andrew Mark Scott, Christopher R. Bebbington, Geoffrey T. Yarranton, Carmelina Murone, Catherine To
-
Patent number: 8637032Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: GrantFiled: September 12, 2012Date of Patent: January 28, 2014Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
-
Patent number: 8632776Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.Type: GrantFiled: February 25, 2011Date of Patent: January 21, 2014Assignee: BioArctic Neuroscience ABInventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
-
Publication number: 20140010821Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.Type: ApplicationFiled: August 16, 2007Publication date: January 9, 2014Inventor: Aili Lao
-
Patent number: 8623369Abstract: Anti-ICAM-1 VHH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of ICAM-1-related pathological conditions including atherosclerotic plaques. The antibodies may also be linked to a therapeutic agent to specifically target and treat ICAM-1-related pathological conditions.Type: GrantFiled: April 27, 2011Date of Patent: January 7, 2014Assignee: National Research Council of CanadaInventors: Abedelnasser Abulrob, Mehdi Arbabi-Ghahroudi, Danica Stanimirovic
-
Patent number: 8623368Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.Type: GrantFiled: October 22, 2010Date of Patent: January 7, 2014Assignee: Hanwha Chemical CorporationInventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Dong Eun Lee, Su Yeon Ryu, Hyun Bo Shim, Kyung Jae Kang
-
Patent number: 8613926Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: GrantFiled: June 6, 2012Date of Patent: December 24, 2013Assignee: Novo Nordisk A/SInventors: Kristian Kjaergaard, Soeren Lund, Soeren Berg Padkjaer
-
Patent number: 8613903Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.Type: GrantFiled: September 10, 2009Date of Patent: December 24, 2013Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Zhengxing Qu, Chien-Hsing Chang
-
Patent number: 8609090Abstract: Specific binding agents that interact with hepatocyte growth factor (HGF) are described. Methods of treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods of detecting the amount of HGF in a sample using a specific binding agent to HGF are described.Type: GrantFiled: July 16, 2004Date of Patent: December 17, 2013Assignees: Amgen Inc., Amgen Fremont Inc.Inventors: Teresa L. Burgess, Angela Coxon, Larry L. Green, Ke Zhang
-
Publication number: 20130330343Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.Type: ApplicationFiled: December 13, 2012Publication date: December 12, 2013Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KGInventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
-
Patent number: 8603481Abstract: A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an antibody fragment maintaining the antibody activity.Type: GrantFiled: October 7, 2004Date of Patent: December 10, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Shigeto Kawai, Masahiko Mihara, Yasuo Koishihara
-
Patent number: 8591900Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: March 30, 2011Date of Patent: November 26, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
-
Patent number: 8586035Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.Type: GrantFiled: February 8, 2008Date of Patent: November 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
-
Patent number: 8586052Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.Type: GrantFiled: April 24, 2012Date of Patent: November 19, 2013Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
-
Publication number: 20130302317Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.Type: ApplicationFiled: March 12, 2013Publication date: November 14, 2013Applicant: University Court of the University of DundeeInventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
-
Publication number: 20130295095Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.Type: ApplicationFiled: June 3, 2011Publication date: November 7, 2013Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
-
Publication number: 20130295088Abstract: The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody.Type: ApplicationFiled: May 10, 2013Publication date: November 7, 2013Inventors: Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller, Ian Machin, Laura Corradini
-
Publication number: 20130295087Abstract: The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.Type: ApplicationFiled: May 10, 2013Publication date: November 7, 2013Inventors: Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller, Ian Machin, Laura Corradini
-
Patent number: 8568725Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: GrantFiled: December 24, 2004Date of Patent: October 29, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Hirano
-
Patent number: 8568718Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: June 8, 2011Date of Patent: October 29, 2013Assignee: Bioalliance C.V.Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
-
Publication number: 20130280269Abstract: The present invention relates to methods that manipulate the level of interaction between the proteins Hsp70 and IRE1?. In particular, the invention relates to methods of manipulating this interaction in order to increase protein yield, and to methods of manipulating this interaction in order to treat diseases associated with abnormal apoptotic activity, including cancer and autoimmune diseases.Type: ApplicationFiled: June 8, 2011Publication date: October 24, 2013Applicant: National University of IrelandInventors: Afshin Samali, Sanjeev Gupta, Aysawaria Deepti
-
Publication number: 20130280270Abstract: A method of treating an inflammatory disease in a subject in need thereof is carried out by administering the subject a gastrin-releasing peptide (GRP) inhibitor in a treatment effective amount. Suitable GRP inhibitors include compounds of the general formula: and pharmaceutically acceptable salt or prodrugs thereof.Type: ApplicationFiled: June 14, 2013Publication date: October 24, 2013Inventors: Mary E. Sunday, W. Michael Foster, Shutang Zhou, Erin Potts
-
Patent number: 8557240Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.Type: GrantFiled: November 15, 2011Date of Patent: October 15, 2013Assignee: Biogen IDEC MA Inc.Inventors: Philip Gotwals, Antonin de Fougerolles, Roy Lobb, Victor E. Kotelianski